Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma

This study has been withdrawn prior to enrollment.
(Study drug supplier withdrew support for the study. Study was withdrawn from the Duke IRB.)
Bristol-Myers Squibb
Information provided by (Responsible Party):
Annick Desjardins, Duke University Medical Center Identifier:
First received: May 4, 2008
Last updated: November 20, 2012
Last verified: November 2012
No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: June 2012
  Estimated Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)